3Billion

3B-NEO is a comprehensive genetic screening service for newborns.

3billion's AI software 3Cnet can predict variants as pathogenic with 2.2 times higher sensitivity than other predictors by learning three types of data together.

3billion's AI software, MIN-T increases the possibility of synthesizing compounds by simulating an existing synthesis process and learning massive synthetic data.

AI-powered variant interpretation platform for clinical decision support

Discover Insightful Articles on Rare Diseases

The page explains factors influencing genetic testing costs, including single-gene tests, whole exome sequencing, cost vs. value, insurance coverage, and family testing.

3billion reduced turnaround time for its 5-week genetic testing services to 4 weeks by improving workflows.

The page covers Autosomal Dominant Polycystic Kidney Disease (ADPKD), its genetic basis, prevalence, and the role of genetic testing and variant interpretation in clinical practice.

3billion marks its 10th anniversary with the “10 Years of Answers, Together” campaign, reflecting on a decade of rare disease diagnostics, more than 100,000 patients tested across 75+ countries, and its expansion from diagnosis to early detection and therapeutics.

3billion is expanding global adoption of GEBRA, its AI-powered genetic variant interpretation platform now used or evaluated in more than 30 countries.

3billion appoints Erik Zmuda, Ph.D., as Vice President of Clinical Genomics and Senior Laboratory Director at 3billion US to lead the buildout of its Austin clinical laboratory, CLIA certification, CAP accreditation, and U.S. rare disease diagnostics expansion.

3billion joins the Korean ARPA-H ARISE project to advance N-of-many ASO therapeutics through genomic and clinical data, AI variant interpretation technology, and its patient network.

3billion continue to challenge ourselves to end the diagnostic odyssey of rare disease patients. Visit and learn what 3billion aims to do

3billion has made an investment.

Apply for next grant program.

3billion invites proposals for research collaborations to explore new discoveries.

3billion provides genetic testing for rare diseases that includes unlimited reanalysis which takes into account newly discovered diseases until diagnosis.

The page lists the latest notices from 3billion, a rare disease diagnostics company.

3billion provides genetic and biochemical tests and analyses, processing personal data from patients, authorized healthcare providers, and medical organizations.

3billion Inc. (hereinafter referred to as “3billion”) specializes in rare disease genetic diagnostic services and newborn genetic screening services (including the Portal Site and NEO Site). Customers who do not agree to these Terms will not be able to use the services provided on the website.